Meeting
2013 Gastrointestinal Cancers Symposium
A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer.
Authors
Andre Konski
Karmanos Cancer Institute, Wayne State University
Andre Konski , Joshua Meyer , Philip Philip , Anthony Shields , Michael Hall , Minsig Choi , Gail Duncan , Beth Adaire , Erin McSpadden , Steven Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00761345
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr268)
DOI
10.1200/jco.2013.31.4_suppl.268
Abstract #
268
Poster Bd #
C16
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC).
First Author: Dana Backlund Cardin
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2011 ASCO Annual Meeting
Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.
First Author: S. R. Palmer
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt